Kaminari Medical: Funding, Investors & Team (Sep 2026)

PROBLEM Insufficient treatment of vulnerable plaque in the coronary arteries lead to costly and health impairing re-catheterizations In 2015, Coronary Artery Disease (CAD) affected 110 million people and resulted in 8.9 million deaths worldwide. CAD occurs when the arteries that supply the heart muscle with blood become hardened and narrowed, due to the buildup of cholesterol and plaque on their inner walls. Current treatment: To open the blocked coronary arteries, 80% of the patients are treated using a Percutaneous Coronary Intervention (PCI). - Of those patients treated with PCI, 12% get a re-catheterization within 12 months after the initial procedure. - Total costs for these re-catheterizations are estimated at $ 3,5 billion. 50% of these re-catheterizations are caused by a type of stenosis called vulnerable plaques, that are formed by fat-filled cells with a thin cover. If the cover ruptures a blood clot is formed, blocking the coronary artery. - If these vulnerable plaques were treated in an early stage, repeat catheterizations could be prevented. SOLUTION Kaminari combines ultrasound (IVUS) and photoacoustic (PA) imaging, providing better information on both plaque location and composition. Visit our website for more details.

Kaminari Medical has raised $2.5M across 1 round on record. The most recent is an undisclosed round of $2.5M announced in Oct 2024.

Kaminari Medical's most recent funding round on record is an undisclosed round of $2.5M, announced in Oct 2024.

FundedIQ lists Verya Daeichin (Founder) at Kaminari Medical.

Kaminari Medical is based in Rotterdam, Zuid-Holland, Netherlands.

Kaminari Medical is in the 1-10 employee band.

Kaminari Medical's latest round of $2.5M is below the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.